The London-based biotechnology company said the funding comes from two innovation grants and will help accelerate platform development while broadening its focus into additional disease areas.

The awards build on previous non-dilutive funding secured by the company, which has received £1.8 million from UK Research and Innovation through Investor Partnership, Biomedical Catalyst and SMART business awards.

Laverock is developing programmable gene-control technologies designed to create disease-responsive advanced therapies. The platform combines single-cell analysis, artificial intelligence and gene regulation tools to enable more precise control of therapeutic cell behaviour.

The company has already demonstrated its technology across several cell types and therapeutic applications, including engineered T cells and macrophages for solid tumours, as well as hypoimmunogenic pancreatic islet cells for Type 1 diabetes.

One of the newly funded projects will focus on scaling the platform for T-cell therapies targeting solid tumours. The programme will use patient-derived datasets, alongside information on intracellular signalling and antigen expression, to identify combinations of therapeutic features that could improve both efficacy and safety.

According to the company, integrating single-cell technologies with AI-based analysis will help identify optimal product characteristics tailored to specific tumour types and enable faster evaluation using patient-derived models.

The second project will support expansion of Laverock’s macrophage-based programmes into non-oncology indications. The company said the work builds on its ability to programme myeloid cell phenotypes and control the expression of therapeutic payloads.

The programme will be conducted through a consortium involving disease specialists and experts across the product development pathway, with the aim of accelerating translation into clinical development.

David Venables, chief executive officer of Laverock Therapeutics, said: “Success in these two highly competitive grant competitions provides further validation of our approach and will enable us to expand our efforts across platform and product development. As we push towards the clinic for our lead programme this additional funding will help unlock the true breadth of what our technology can achieve. We can’t wait to get started!”

Interest in AI-enabled drug discovery and cell therapy development continues to grow across the biotechnology sector as companies seek new approaches to improve target selection, optimise therapeutic design and shorten development timelines.

For Laverock, the latest funding provides additional support for both technology development and diversification of its pipeline. While the company has established programmes in oncology, the new grants will allow it to explore broader therapeutic opportunities while continuing preparations for clinical development of its lead candidate.

The awards also represent further external validation of the company’s platform strategy at a time when investors and funding bodies are increasingly focused on technologies that can improve the precision, safety and effectiveness of advanced therapies.